Nuvation Bio annual r&d spending
2020
2021
2022
2023
2024
2025
Nuvation Bio R&D Spending Growth & History (NUVB)
Nuvation Bio's r&d spending was $115.1M for fiscal 2025.
View full Nuvation Bio company overviewNuvation Bio annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $115.1M | $16.0M | +16.13% |
| 2024 | 2024-12-31 | $99.1M | $27.8M | +39.04% |
| 2023 | 2023-12-31 | $71.3M | −$16.5M | −18.82% |
| 2022 | 2022-12-31 | $87.8M | $18.8M | +27.20% |
| 2021 | 2021-12-31 | $69.0M | $36.4M | +111.75% |
| 2020 | 2020-12-31 | $32.6M | — | — |
Nuvation Bio quarterly r&d spending
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $30.7M | $3.3M | +12.06% |
| Q1 2026 | 2026-03-31 | $35.0M | $10.4M | +42.46% |
| Q4 2025 | 2025-12-31 | $34.3M | $5.0M | +17.06% |
| Q3 2025 | 2025-09-30 | $28.8M | $1.1M | +4.02% |
| Q2 2025 | 2025-06-30 | $27.4M | −$1.9M | −6.45% |
| Q1 2025 | 2025-03-31 | $24.6M | $11.8M | +91.57% |
| Q4 2024 | 2024-12-31 | $29.3M | $13.9M | +90.86% |
| Q3 2024 | 2024-09-30 | $27.7M | $9.2M | +49.40% |
| Q2 2024 | 2024-06-30 | $29.2M | $10.7M | +57.33% |
| Q1 2024 | 2024-03-31 | $12.8M | −$5.9M | −31.64% |
| Q4 2023 | 2023-12-31 | $15.4M | −$1.5M | −9.00% |
| Q3 2023 | 2023-09-30 | $18.6M | −$2.7M | −12.83% |
| Q2 2023 | 2023-06-30 | $18.6M | −$10.3M | −35.72% |
| Q1 2023 | 2023-03-31 | $18.8M | −$1.9M | −9.37% |
| Q4 2022 | 2022-12-31 | $16.9M | −$5.1M | −23.33% |
| Q3 2022 | 2022-09-30 | $21.3M | $4.2M | +24.37% |
| Q2 2022 | 2022-06-30 | $28.9M | $14.9M | +106.09% |
| Q1 2022 | 2022-03-31 | $20.7M | $4.8M | +30.54% |
| Q4 2021 | 2021-12-31 | $22.0M | $12.7M | +135.67% |
| Q3 2021 | 2021-09-30 | $17.1M | $8.5M | +98.47% |
| Q2 2021 | 2021-06-30 | $14.0M | $6.7M | +91.07% |
| Q1 2021 | 2021-03-31 | $15.9M | $8.6M | +117.67% |
| Q4 2020 | 2020-12-31 | $9.3M | — | — |
| Q3 2020 | 2020-09-30 | $8.6M | — | — |
| Q2 2020 | 2020-06-30 | $7.3M | — | — |
| Q1 2020 | 2020-03-31 | $7.3M | — | — |
Nuvation Bio r&d spending trends
Over the last five fiscal years, Nuvation Bio's r&d spending increased from $32.6M to $115.1M, a change of $82.5M. The latest reported quarter, Q2 2026, shows $30.7M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nuvation Bio source filings ↗